News
There is a shift from treating a disease to preventing it, says PhRMA chief medical officer Dr. Mike Ybarra.
Give patients the financial options that empower them to take charge of their own health, says Beto Casellas of Synchrony.
More than half of employers plan to implement programs that will reduce total costs, a WTW survey finds.
Prices for 25 drugs are expected to decrease for Medicare beneficiaries starting in 2026 and continuing into 2027.
Humana blames higher industry cut points and one contract decreasing to a 3.5-star rating from a 4.5-star rating in 2024.
It's the second consecutive month in which operating margins tightened, Strata's data shows.
The report compares cost, care, patient experience and more to brick-and-mortar care, ahead of the expiration of the waiver.
The potential return on investment from reducing these inequities could be enormous, a Deloitte analysis finds.
Various forms of a potential separation are reportedly under consideration, though specifics remain unclear.
The drugmaker says it believes the rebate model is legally permissible and needed to improve the integrity of the 340B program.